Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

Geert Leroux-Roels; Cathy Maes; Frédéric Clement; Frank van Engelenburg; Marieke van den Dobbelsteen; Michael Adler; Mario Amacker; Lucia Lopalco; Morgane Bomsel; Anick Chalifour; Sylvain Fleury

doi:10.1371/journal.pone.0055438

Loading metrics

Open Access

Peer-reviewed

Research Article

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

Geert Leroux-Roels,

Affiliation Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium
⨯
Cathy Maes,

Affiliation Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium
⨯
Frédéric Clement,

Affiliation Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium
⨯
Frank van Engelenburg,

Affiliation Kinesis Pharma B.V., Breda, The Netherlands
⨯
Marieke van den Dobbelsteen,

Affiliation Kinesis Pharma B.V., Breda, The Netherlands
⨯
Michael Adler,

Affiliation Chimera Biotec GmbH, Dortmund, Germany
⨯
Mario Amacker,

Affiliation Pevion Biotech AG, Ittigen/Bern, Switzerland
⨯
Lucia Lopalco,

Affiliation Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
⨯
Morgane Bomsel,

Affiliations Mucosal Entry of HIV-1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, Université Paris Descartes, Paris, France, CNRS UMR8104, Paris, France, INSERM U1016, Paris, France
⨯
Anick Chalifour,

Affiliation Mymetics Corporation, Epalinges, Switzerland
⨯
Sylvain Fleury

* E-mail: sylvain.fleury@mymetics.com

Affiliation Mymetics Corporation, Epalinges, Switzerland
⨯

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

Geert Leroux-Roels,
Cathy Maes,
Frédéric Clement,
Frank van Engelenburg,
Marieke van den Dobbelsteen,
Michael Adler,
Mario Amacker,
Lucia Lopalco,
Morgane Bomsel,
Anick Chalifour

Published: February 20, 2013
https://doi.org/10.1371/journal.pone.0055438

Reader Comments

Post a new comment on this article

Media Coverage of This Article

Posted by PLOS_ONE_Group on 23 Feb 2013 at 01:05 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: Press Release
Title: “February 21, 2013 - Data published in PLOS ONE show Mymetics'HIV-1 Innovative vaccine is safe and elicits strong immunogenicity”
http://www.mymetics.com/i...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Vaccination and immunization
Is the Subject Area "Vaccination and immunization" applicable to this article?

Thanks for your feedback.
Rectum
Is the Subject Area "Rectum" applicable to this article?

Thanks for your feedback.
Enzyme-linked immunoassays
Is the Subject Area "Enzyme-linked immunoassays" applicable to this article?

Thanks for your feedback.

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

Reader Comments

Post Your Discussion Comment

Why should this posting be reviewed?

Thank You!

Media Coverage of This Article

Posted by PLOS_ONE_Group on 23 Feb 2013 at 01:05 GMT